Tempest Therapeutics (TPST) Competitors $6.30 -0.40 (-5.97%) Closing price 03:59 PM EasternExtended Trading$6.52 +0.22 (+3.49%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TPST vs. MGNX, BDTX, CTNM, ENTX, KYTX, OPTN, HLVX, IMUX, CRDL, and ZNTLShould you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include MacroGenics (MGNX), Black Diamond Therapeutics (BDTX), Contineum Therapeutics (CTNM), Entera Bio (ENTX), Kyverna Therapeutics (KYTX), OptiNose (OPTN), HilleVax (HLVX), Immunic (IMUX), Cardiol Therapeutics (CRDL), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry. Tempest Therapeutics vs. MacroGenics Black Diamond Therapeutics Contineum Therapeutics Entera Bio Kyverna Therapeutics OptiNose HilleVax Immunic Cardiol Therapeutics Zentalis Pharmaceuticals Tempest Therapeutics (NASDAQ:TPST) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking. Which has more risk & volatility, TPST or MGNX? Tempest Therapeutics has a beta of -1.78, indicating that its stock price is 278% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Do analysts prefer TPST or MGNX? Tempest Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 356.27%. MacroGenics has a consensus target price of $6.13, suggesting a potential upside of 299.02%. Given Tempest Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tempest Therapeutics is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50MacroGenics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40 Is TPST or MGNX more profitable? Tempest Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. MacroGenics' return on equity of -89.42% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -187.44% -82.61% MacroGenics -69.07%-89.42%-38.57% Does the media refer more to TPST or MGNX? In the previous week, MacroGenics had 6 more articles in the media than Tempest Therapeutics. MarketBeat recorded 11 mentions for MacroGenics and 5 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 0.71 beat MacroGenics' score of -0.41 indicating that Tempest Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in TPST or MGNX? 22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 4.7% of Tempest Therapeutics shares are held by company insiders. Comparatively, 13.0% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in TPST or MGNX? MacroGenics received 325 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. However, 65.38% of users gave Tempest Therapeutics an outperform vote while only 61.97% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformTempest TherapeuticsOutperform Votes10265.38% Underperform Votes5434.62% MacroGenicsOutperform Votes42761.97% Underperform Votes26238.03% Which has stronger earnings & valuation, TPST or MGNX? MacroGenics has higher revenue and earnings than Tempest Therapeutics. MacroGenics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$29.49M-$17.98-0.37MacroGenics$152.43M0.64-$9.06M-$0.89-1.72 SummaryMacroGenics beats Tempest Therapeutics on 12 of the 17 factors compared between the two stocks. Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TPST vs. The Competition Export to ExcelMetricTempest TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.14M$6.55B$5.40B$8.53BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-4.289.1626.7419.97Price / SalesN/A258.53394.93122.22Price / CashN/A65.8538.2534.62Price / Book4.736.546.874.59Net Income-$29.49M$143.98M$3.23B$248.18M7 Day Performance0.38%4.65%5.01%2.15%1 Month Performance-7.52%9.18%12.82%16.14%1 Year Performance-84.95%-1.33%17.63%8.06% Tempest Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TPSTTempest Therapeutics1.9568 of 5 stars$6.30-6.0%$30.00+376.2%-84.2%$23.20MN/A-4.1220Analyst RevisionMGNXMacroGenics3.5583 of 5 stars$1.59+11.2%$7.43+367.2%-63.1%$100.31M$148.34M-1.01430News CoverageAnalyst ForecastGap DownBDTXBlack Diamond Therapeutics3.3114 of 5 stars$1.75+6.7%$14.60+734.3%-55.7%$99.19MN/A-1.3290News CoveragePositive NewsCTNMContineum Therapeutics2.2039 of 5 stars$3.83-1.0%$23.75+520.1%-75.6%$99.09M$50M-0.7831Earnings ReportAnalyst ForecastENTXEntera Bio1.8091 of 5 stars$2.15flat$10.00+365.1%-10.4%$97.66M$181,000.00-8.2720News CoveragePositive NewsGap UpKYTXKyverna Therapeutics2.3955 of 5 stars$2.21+4.7%$18.33+729.6%-83.4%$95.51M$7.03M-0.6496News CoverageAnalyst RevisionGap UpOPTNOptiNose2.997 of 5 stars$9.42+0.3%$9.00-4.5%-46.7%$95.40M$78.23M-2.24190News CoverageAnalyst ForecastAnalyst RevisionHLVXHilleVax2.5015 of 5 stars$1.89-0.5%$3.00+58.7%-86.1%$94.77MN/A-0.6120News CoveragePositive NewsIMUXImmunic2.4106 of 5 stars$0.99-2.3%$13.20+1,237.8%-24.5%$94.54MN/A-0.8070Earnings ReportGap DownCRDLCardiol Therapeutics1.6121 of 5 stars$1.13-1.7%$8.40+643.4%-48.6%$93.35MN/A-2.9020Negative NewsZNTLZentalis Pharmaceuticals1.9616 of 5 stars$1.29+4.9%$8.24+539.1%-89.1%$92.82M$67.43M-0.52160News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies MGNX Alternatives BDTX Alternatives CTNM Alternatives ENTX Alternatives KYTX Alternatives OPTN Alternatives HLVX Alternatives IMUX Alternatives CRDL Alternatives ZNTL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TPST) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TPST Stock Free TPST Stock Alerts